The VAD Journal: The journal of mechanical assisted circulation and heart failure

Brano Heart Failure Forum 2019 Conference Proceeding Paper

Transcutaneous Energy Transmission: Can we do it
now?

Yuriy Pya, MD
National Research Cardiac Surgery Center, Astana, Kazakhstan
Corresponding author: piayury@mail.ru

Citation: Pya Y.
Transcutaneous Energy
Transmission: Can we do it
now? The VAD Journal. 2020;
6(2):e2020624.
https://doi.org/10.11589/vad/e
2020624
Editor-in-Chief: Maya Guglin,
University of Kentucky
Received: June 26, 2020
Accepted: July 7, 2020
Published Online: October 6,
2020
© 2020 The Author(s). This is an

open access article published
under the terms of the Creative
Commons AttributionNonCommercial 4.0 International
License
(https://creativecommons.org/lice
nses/by-nc/4.0/), which permits
unrestricted non-commercial use,
distribution, and reproduction in
any medium, provided that the
original author(s) and the
publication source are credited.
Funding: Not applicable
Competing interests: None

Keywords: gastrointestinal bleeding, left ventricular assist device,
arteriovenous malformation

Abstract
The percutaneous driveline used in contemporary LVADs presents a continuous
risk of infection for the duration of support. Minimizing infection in durable
mechanical circulatory support systems requires total implantation of all
components and energy transfer by means other than percutaneous drivelines. A
novel coplanar energy transfer (CET) system, similar to the original
transcutaneous energy transfer (TET) design, is unique by incorporating two large
rings with coil-within-the-coil topology to ensure strong resonance power. The CET
system consists of an internal integrated controller, a battery coupled with an
internal thoracic coil ring, and the LVAD pump. External equipment includes a
power transmission belt with an external controller, a battery, and wristwatch
monitor. The CET system is adaptable to multiple LVAD designs, though the Jarvik
2000 (Jarvik Heart, Inc., New York, NY) with postauricular power cable was used
in the initial clinical cases. Two male patients, ages 51 years and 24 years,
underwent implantation of the CET/Jarvik 2000 system for the bridge to transplant
indication. One patient experienced a stroke and device thrombosis which led to
termination of LVAD support while the patient waited for transplantation. The
second patient underwent successful transplant after two months of support. The
CET functioned as intended in both patients. Larger, multicenter, controlled clinical
trials are necessary to determine the long-term safety and efficacy of the CET
technology.

The VAD Journal: Transcutaneous Energy Transmisison

Page 1 of 6

The VAD Journal: The journal of mechanical assisted circulation and heart failure

Introduction
Infection following left ventricular assist device (LVAD) implantation is a leading
cause of morbidity, mortality, hospital readmission, and high cost of care.1,2 The
required percutaneous driveline for contemporary LVADs presents a continuous
risk of infection for the duration of support. Minimizing infection in durable
mechanical circulatory support systems requires total implantation of all
components and energy transfer by means other than percutaneous drivelines.
Elimination of the percutaneous driveline by integration of transcutaneous energy
transfer (TET) has been performed successfully in earlier designs of the LVAD and
total artificial heart,3,4 but is not currently incorporated into the widely used LVAD
systems today.
A novel coplanar energy transfer (CET) system, similar to the original TET design,
is unique by incorporating two large rings with coil-within-the-coil topology to
ensure strong resonance power. The CET system (Leviticus Cardio, Ltd., Petach
Tikva, Israel) is designed for total implantation of an LVAD with wireless power and
control with no percutaneous driveline. The system is designed to be adaptable for
use in multiple blood pump systems. An internal battery can provide greater than 8
hours of continuous untethered operation. The initial clinical implants have been
performed at the National Research Cardiac Surgery Center, Astana,
Kazakhstan.5 In this report, we provide a description of the CET system and the
clinical status of the first patients implanted with the system.

Methods
CET system description
The CET system consists of an internal integrated controller, a battery coupled
with an internal thoracic coil ring, and the LVAD pump (Figure 1A). External
equipment includes a power transmission belt with an external controller, a battery,
and wristwatch monitor (Figure 1B). The integrated controller and battery are
coupled with an internal thoracic coil ring. The CET system allows a greater
distance between transmitter and receiver coils and can reach power levels of up
to 30 Watts with 75% efficiency. The coil ring is placed around the lung and fixed
to the chest wall. Power is received by the coil ring from the external power
transmission belt. The internal controller and battery control the power circuits,
activate the LVAD’s brushless DC motor, communicate with the external controller,
and control the battery charging circuits. The battery provides power backup and
enables several hours of operation without the external transmission belt. The user
watch provides status and alarm information for the patient. The power
transmission belt transmits power to the internal receiver coil by magnetic
coupling. The external controller runs the power transmission control algorithm,
communicates with the pump, and pushes power to the belt, using special power
driver circuits. The external battery provides the main power source to the
implanted pump. A tablet is used mainly for patient-specific configuration during
device startup.
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Figure 1. The CET system internal components (A): Jarvik 2000 pump with
postauricular power cable, coil ring, and controller/battery and external
components (B): power transmission belt, controller and battery, and user
wristwatch.

The CET system is adaptable to multiple LVAD designs, though the Jarvik 2000
(Jarvik Heart, Inc., New York, NY) with postauricular power cable was used in the
initial clinical cases.6 For safety in the initial clinical tests, employment of the Jarvik
2000 system with a retroauricular pedestal that connects to an external power
source may be used as a backup in case of component failure of the CET system.
The original Jarvik 2000 controller, battery, and monitor are replaced by the CET
system controller.
Implantation
Implantation is accomplished through a median sternotomy approach. The power
cable is tunneled from the thorax to the base of the skull, where it is attached to
the skull pedestal. The lung is deflated, and the coil size is determined by sizers.
The coil is positioned horizontally around the circumference of the lower portion of
a pleural cavity. A pocket for the controller-battery is created between the serratus
and latissimus dorsi muscles, along the lateral thoracic. Cardiopulmonary bypass
is started, the pump is implanted into the left ventricle, and a parallel V-shaped
driveline from the pump and internal coil are tunneled through an intercostal space
to the controller. Both connectors are secured, the pump is started, and
cardiopulmonary bypass is weaned.
Patients
Two male patients, ages 51 years (Patient A) and 24 years (Patient B), underwent
implantation of the CET/Jarvik 2000 system for the bridge to transplant indication
(Table 1). Both patients had NYHA class IV heart failure symptoms and were
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classified as INTERMACS profile 3. Patient A experienced an ischemic stroke
(modified Rankin Scale score >3) and required prolonged intensive care and
rehabilitation. Computed tomography revealed pump thrombosis and occlusion of
the outflow, consistent with high power requirements from the CET. A
multidisciplinary team decided to terminate the LVAD and CET operation, and the
patient was started on intravenous inotropic support. The patient remained stable
with adequate organ function and was on the heart transplant waiting list.
Implantation and recovery for Patient B was uneventful, and he was discharged
from the hospital 30 days after implantation. After 3 days in the intensive care unit,
Patient B became ambulatory and was without complications. He underwent
successful heart transplant after 2 months of support. During outpatient support,
the patient participated in common activities, including walking, shopping, and
swimming.
Table 1. Patient Characteristics
Age (years)
Gender
Body surface area (m2)
Etiology
Left ventricular ejection fraction
(%)
Cardiac index (L/m2)
Pulmonary wedge pressure
(mmHg)
Central venous pressure
NYHA class
INTERMACS profile

Patient A
51
Male
2.02
Ischemic
11

Patient B
24
Male
1.89
Non-ischemic
22

1.9
24

2.2
20

6
IV
3

5
IV
3

System performance
There were no malfunctions of the CET/Jarvik 2000 LVAD system. The CET
system functioned as designed in both patients. Untethered operation was
accomplished for 8.5 hours before the first alert for battery recharge. These alerts
occur when 1 hour of power remains. Critical alarms occur at low battery levels for
immediate recharge of the internal battery.

Discussion
These initial cases using the CET/Jarvik 2000 LVAD system demonstrate the
feasibility of durable LVAD support without the need for a percutaneous driveline.
This represents an important advancement for long-term mechanical circulatory
support, as the continuous risk of device-related infections may be greatly
reduced. Device-related infection, and in particular percutaneous driveline
infection, is a long-standing problem that significantly contributes to morbidity and
mortality.7-9 Elimination of the percutaneous driveline from durable mechanical
circulatory support systems may enhance survival with less morbidity and overall
cost of care in the future.
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Concern for safety in a totally implanted LVAD system is paramount. In these initial
studies, an externalized postauricular connector was employed as a backup in
case of any failure of the CET system⎯it was not utilized in these cases. Also, the
selected patients were transplant candidates, which offered a secondary bailout, if
needed. The CET system did not reveal any negative effects on lung function, and
chest x-rays and CT scans did not show signs of atelectasis or compression of the
lung. The long-term effects of the CET implant on pulmonary function remains
unknown.
The CET system was developed with the intent to be integrated with most durable
mechanical circulatory support systems. Long-term animal studies have
demonstrated feasibility for CET use with other available devices.5 Larger,
multicenter, controlled clinical trials are necessary to determine the long-term
safety and efficacy of the CET technology. At the time of this writing, no additional
implants have been performed pending further technology and regulatory
developments.

Discussion
The authors would like to acknowledge Tim Myers for editorial assistance and
special thanks to Leviticus-Cardio, Ltd for their permission to use the images seen
in Figure 1.
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